Litcius/Paper detail

Effect of TAT-DOX-PEG irradiated gold nanoparticles conjugates on human osteosarcoma cells

Raoul Vasile Lupușoru, Daniela Angelica Pricop, Cristina Mariana Urîtu, Adina Arvinte, Adina Coroabǎ, Irina Eşanu, Mirela‐Fernanda Zaltariov, Mihaela Silion, Cipriana Ştefănescu, Mariana Pinteală

2020Scientific Reports33 citationsDOIOpen Access PDF

Abstract

. The toxicity level of gold conjugates after their functionalization with DOX and TAT peptide was also evaluated. The AuNPs were prepared using the modified Turkevich method and exposed to visible light at a wavelength of 520 nm prior their PEGylation. The optical properties were analyzed by UV-vis spectroscopy, the surface modification was investigated using FTIR and XPS spectroscopies and their sizes and morphologies were evaluated by TEM and DLS techniques. DOX and TAT peptide were linked to the surface of PEGylated AuNPs by reacting their amino groups with glycidyloxypropyl of PEGylated DOX or TAT conjugates under mild conditions at room temperature and in the presence of ethanol as catalyst. The conjugates containing DOX or DOX and TAT have been characterized by fluorescence and FTIR techniques. The changes of electrochemical features were observed using cyclic voltammetry, suggesting a better stability of irradiated nanoparticles. By mass spectrometry it was confirmed that the compounds of interest were obtained. The cell viability test showed that irradiated and non-irradiated nanoparticles coated with PEG are not toxic in normal cells. Tumor cell viability analysis showed that the PEGylated nanoparticles modified with DOX and TAT peptide were more effective than pristine DOX, indicating cytotoxicity up to 10% higher than non-irradiated ones.

Topics & Concepts

OsteosarcomaColloidal goldPEG ratioCancer researchNanoparticleConjugateIrradiationChemistryMedicineMaterials scienceNanotechnologyNuclear physicsEconomicsFinanceMathematicsPhysicsMathematical analysisNanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryNanoplatforms for cancer theranostics